Sarepta Therapeutics (SRPT) : Investors lapped up stocks on upticks to the tune of $0.83 million in the Tuesdays trading session. The trading value on downticks was comparatively at $0.65 million and the uptick to downtick ratio of 1.28 indicates continuous buying by the bulls. The net money flow into the stock was $0.18 million. Upticks saw transactions worth $0.38 clearly indicating buying by large investors. The total money flow for block trades stood at $0.38 million, which is a positive for the stock in the long-term. Sarepta Therapeutics (SRPT) fell $0.04 during the day at $21.33, a drop of -0.19% over the previous days close. However, for the week, the stock is -5.7%, compared to the previous week.
The company Insiders own 10.9% of Sarepta Therapeutics shares according to the proxy statements. Institutional Investors own 73.35% of Sarepta Therapeutics shares. During last six month period, the net percent change held by insiders has seen a change of 4.44%. In an insider trading activity, The Securities and Exchange Commission has divulged in a Form 4 filing that the director of Sarepta Therapeutics, Inc., Behrens M Kathleen had purchased shares worth of $1,165,500 in a transaction dated on March 14, 2016. A total of 75,000 shares were purchased at a price of $15.54 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Shares of Sarepta Therapeutics, Inc. rose by 8.53% in the last five trading days and 10.28% for the last 4 weeks. Sarepta Therapeutics, Inc. has dropped 2.14% during the last 3-month period . Year-to-Date the stock performance stands at -42.98%.
Sarepta Therapeutics (NASDAQ:SRPT): stock turned positive on Tuesday. Though the stock opened at $21.5, the bulls momentum made the stock top out at $22.44 level for the day. The stock recorded a low of $21.02 and closed the trading day at $22, in the green by 2.95%. The total traded volume for the day was 3,066,788. The stock had closed at $21.37 in the previous days trading.
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates, including its lead DMD product candidate, eteplirsen, which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases.